Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth, with a pipeline designed to target critical biological pathways for anti-tumor response. Its lead product candidate, tovecimig (formerly CTX-009), is a bispecific antibody targeting DLL4 and VEGF-A, currently in a Phase 2/3 trial in the United States for biliary tract cancer. Other pipeline candidates include CTX-471, an agonistic antibody targeting CD137; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1; and CTX-10726, a bispecific antibody targeting PD-1 and VEGF-A. The company utilizes its proprietary StitchMabs and common light chain platforms for antibody discovery. Compass holds exclusive global rights to tovecimig outside of South Korea, licensed from ABL Bio, while South Korean rights are held by Handok Pharmaceuticals and China rights are out-licensed to Elpiscience Biopharmaceuticals. The company was co-founded in 2014.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage compasstherapeutics.com
Sector Healthcare IR page investors.compasstherapeutics.com
Tags
oncology, bispecific antibodies, angiogenesis, immune checkpoint inhibitors, biliary tract cancer, solid tumors, antibody discovery, tovecimig, CTX-009, CTX-471, CTX-8371, CTX-10726, StitchMabs, ABL Bio, Handok Pharmaceuticals, Elpiscience Biopharmaceuticals
Press page —

Metrics

Valuation  
Market cap $ 106.252M
Market cap (USD) $ 106.252M
P/E -1.28
PEG —
P/BV 0.75
P/S 125.00
P/OCF -1.73
P/FCF -1.72
Dividend yield —
Turnover / mcap —
Returns  
ROE -41.3%
ROI -38.0%
ROIC -31.2%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score -46.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 0 850K — — — — —
Net profit -66.489M -49.375M -42.494M -39.225M -82.181M -29.5M -34.744M
Free cash flow -49.168M -44.899M -40.648M -34.337M -21.234M -26.909M -32.207M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 5.37 1.45 1.56 5.03 3.17 — —
Price performance 12m 2.7 -0.07 -0.69 0.59 — — —

Filed figures

Figure Dec 2018 Mar 2019 Dec 2019 Mar 2020 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — 5.58M — 7.47M 0.00 — — — —
Borrowings, non-current (USD) — — 9.29M — 1.87M 0.00 — — — —
Lease liabilities (USD) — — — — 0.00 4.04M 2.94M 1.73M 6.63M 9.83M
Cash and deposits (USD) 4,679 4,866 1,144 3,745 47.1M 145M 34.9M 24.2M 43.5M 30.6M
Right-of-use assets (USD) — — — — 0.00 4.09M 2.97M 1.78M 6.73M 9.1M
Net debt (borrowings + leases - cash) (USD) — — -10.4M — -37.7M -140M — — — —
Cash flow detail
Operating cash flow (USD) — -32,759 -31.7M -32,106 -26.8M -19.7M -34.1M -40.6M -44.9M -49.1M
Purchases of property, plant and equipment (USD) — — -466,000 — -106,000 -1.57M -212,000 -30,000 -44,000 -25,000
Change in payables (cash effect) (USD) — 3,278 -1.1M 5,377 432,000 -194,000 2.52M 708,000 -1.84M -664,000
Interest paid (cash effect) (USD) — — -1.12M — -854,000 -370,000 0.00 — — —
Share-based compensation (USD) — — 915,000 — 4.02M 4.03M 5.33M 6.12M 8.56M 8.37M
Free cash flow (OCF - PPE - intangibles) (USD) — — -32.2M — -26.9M -21.2M -34.3M -40.6M -44.9M -49.2M
Income detail
Research and development expense (USD) — — 22.4M — 14.9M 20.3M 30M 38.1M 42.3M 56M
↳ 5y CAGR +13.5% +30.3%
Total comprehensive income (USD) — — — — — -82.2M -39.5M -42.2M -49.2M -66.4M
Comprehensive income to owners (USD) — — — — — -82.2M -39.5M -42.2M -49.2M -66.4M
Reported Feb 14, 2019 Jul 1, 2019 Mar 5, 2021 Jun 8, 2020 Aug 16, 2021 Mar 15, 2023 Mar 15, 2023 Mar 21, 2024 Feb 27, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Compass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA.

Data from the COMPANION-002 study of tovecimig, including newly disclosed durability of response and crossover-adjusted OS analyses, were published in the Journal of Clinical Oncology and presented at the 2026 ESMO Congress in October.

CTX-8371 (PD-1 x PD-L1 bispecific antibody) Phase 1 cohort expansions continue to enroll patients with triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer based on earlier responses in these indications. An update on the study is expected later this year.

Data demonstrating a novel mechanism of action for CTX-10726 (PD-1 x VEGF-A bispecific antibody) was presented at the SITC Annual Meeting, highlighting its differentiated profile in the field. An update on the study is expected later this year.

$163 million in cash and marketable securities at the end of Q3 2026, which is expected to fund operations into 2028.

BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc.

Nov 06, 2026 at 9:00 AM EST

PDF Version

  • CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent cleavage of PD-1 receptors from T cells resulting in conversion of PD-1 positive T cells into PD-1 negative T cells.

  • PD-1 receptor cleavage by CTX-10726 was only observed in the presence of VEGF-A, suggesting targeted activity in the tumor microenvironment.

  • A Phase 1 dose-escalation study of CTX-10726 in patients in the post-checkpoint setting with advanced solid tumors, including renal cell, gastroesophageal, endometrial, and hepatocellular cancers, is ongoing.

  • In checkpoint inhibitor resistant preclinical mouse models, the combination of CTX-10726 and Compass’s CD137 agonist, CTX-471, inhibited tumor growth more than either agent alone.

BOSTON, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, will present data on the novel mechanism of action for CTX-10726 at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting. CTX-10726 is currently in a Phase 1 dose-escalation study in patients in the post-checkpoint setting with multiple types of advanced solid tumors.

Data highlights from the presentation include:

  • **Novel PD-1 Cleavage Mechanism.**In addition to the expected dual blockade of VEGF-A and PD-1, preclinical studies also revealed a novel mechanism of action for CTX-10726. Specifically, the multimerization of CTX-10726 facilitates the cleavage and removal of PD-1 from the surface of T cells, converting PD-1 positive T cells into PD-1 negative T cells and extending the mechanism beyond simply checkpoint blockade and angiogenesis inhibition.

  • **VEGF-A Enhanced Potency.**Adding VEGF-A increased the potency of CTX-10726 approximately ten-fold in a human immune-cell assay measuring interferon-gamma production, reducing the EC50 from 2.0 to 0.2 nM. In vitro studies showed PD-1 receptor cleavage by CTX-10726 in the presence of VEGF-A compared to PD-1 receptor internalization in the absence of VEGF-A. Neither pembrolizumab nor bevacizumab alone demonstrate comparable PD-1 cleavage. Two in vivo models further demonstrated the VEGF-A-dependent nature of PD-1 receptor cleavage by CTX-10726.

  • Combined Activity with CTX-471. A mouse surrogate of CTX-10726 combined with CTX-471 (CD137 agonist antibody) further enhanced anti-tumor activity in mouse models, accompanied by coordinated upregulation of chemokines, interferon-stimulated genes, and inflammatory cytokines. These changes were associated with increased immune cell recruitment and establishment of a more permissive tumor microenvironment.

“These data reveal a new and differentiated mechanism of action for CTX-10726, setting it apart in this exciting new class of therapeutics,” said Thomas Schuetz, MD, PhD, Chief Executive Officer. “We believe PD-1 receptor cleavage results in more potent and potentially more durable checkpoint inhibition, which supports and explains what we saw in our earlier studies. The dependence of this mechanism on VEGF links a traditionally anti-angiogenic agent directly to checkpoint control and may enhance the activity of CTX-10726 within VEGF-A-rich tumor microenvironments. We are also encouraged by the combination results with CTX-471 in checkpoint-resistant models, supporting further investigation of these complementary approaches.”

The Phase 1 multiple ascending dose-escalation study of CTX-10726 includes four dosing cohorts (0.3, 1.0, 3.0, and 10.0 mg/kg) in a 3+3 format. The multi-center study is enrolling post-checkpoint patients with a prioritized set of locally advanced, unresectable or metastatic malignancies, including renal cell carcinoma, gastroesophageal cancer, hepatocellular carcinoma, and endometrial cancer, in whom standard of care therapies have failed.

Details of the presentation are as follows:

**Title:**VEGF-dependent cleavage of cell surface PD-1 mediated by CTX-10726, a novel PD-1×VEGF-A bispecific antibody **Date & Time:**Saturday, November 7, 2026 from 10:00 AM–2:00 PM MT and 6:00–8:10 PM MT **Poster number:**678 **Location:**Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4-5

A copy of the presentation materials can be accessed on the Compass website at https://www.compasstherapeutics.com/pipeline/ once the presentation has concluded.

About CTX-10726 CTX-10726 is a tetravalent PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass. CTX-10726 is designed to synergistically deliver VEGF-A blockade and checkpoint inhibition, potentially applicable to multiple solid tumor indications. The bispecific antibody demonstrates a highly stable structure with high affinity target binding. CTX-10726 exhibits more potent PD-1 suppression and a novel mechanism of action compared with data reported for other drugs in the class.

About Compass Therapeutics Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. Compass is advancing their discovery candidates through clinical development to commercial-stage assets. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. For more information, visit www.compasstherapeutics.com.

Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass’s financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass’s product candidates, including their development and clinical trial milestones such as the expected trial design, timing of enrollment, patient dosing and data readouts, regulatory plans with respect to Compass’s product candidates and the therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass’s latest Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC.

Investor Contact [email protected] Media Contact Anna Gifford, Chief of Staff [email protected] 617-500-8099

News Release image

IR Contact

[email protected]

Media Contact

Anna Gifford, Chief of Staff

[email protected]

Email Alerts

![Compass Therapeutics Logo](https://investors.compasstherapeutics.com/sites/g/files/knoqqb72701/themes/site/nir_pid7612/client/wp-content/themes/compasstx2019/assets/images/icon_menu.svg) ![Compass Therapeutics Logo](https://investors.compasstherapeutics.com/sites/g/files/knoqqb72701/themes/site/nir_pid7612/client/wp-content/themes/compasstx2019/assets/images/icon_menu.svg)

Nov 02, 2026 at 9:00 AM EST

PDF Version

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November/this quarter.

Details are as follows:

Guggenheim 3rd Annual Healthcare Innovation Conference Date: Monday, November 9, 2026 Time: 1:30 PM ET Webcast Link: https://event.summitcast.com/view/

Stifel 2026 Healthcare Conference Date: Wednesday, November 11, 2026 Time: 11:20 AM ET Webcast Link: https://event.summitcast.com/view/

**Virtual/Replay availability:**Presentations will be archived on Compass’ Events page.

Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

About Compass Therapeutics Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company dedicated to transforming the standard of care for patients with cancer through the discovery and development of innovative antibody-based therapeutics. The company leverages deep expertise in tumor biology and proprietary antibody engineering technologies to develop differentiated therapies that target the intersection of angiogenesis, immune activation, and tumor-driven immunosuppression. Compass has a robust pipeline of novel product candidates designed to address significant unmet needs and improve outcomes for patients with cancer. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com

Investor Contact [email protected]

Media Contact Anna Gifford, Chief of Staff [email protected] 617-500-8099

News Release image

IR Contact

[email protected]

Media Contact

Anna Gifford, Chief of Staff

[email protected]

Email Alerts

![Compass Therapeutics Logo](https://investors.compasstherapeutics.com/sites/g/files/knoqqb72701/themes/site/nir_pid7612/client/wp-content/themes/compasstx2019/assets/images/icon_menu.svg) ![Compass Therapeutics Logo](https://investors.compasstherapeutics.com/sites/g/files/knoqqb72701/themes/site/nir_pid7612/client/wp-content/themes/compasstx2019/assets/images/icon_menu.svg)

Prompts

Compass Therapeutics, Inc. (ticker CMPX), listed in United States.

Company History

Date Change Detail
Jun 23, 2020 Renamed OLIVIA VENTURES, INC. → COMPASS THERAPEUTICS, INC.

ETFs Holding Compass Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FESM 0.04% 1,122,143 $ 2.457M Jun 30, 2026
FSEG 0.03% 700 $ 1,533.00 Jun 30, 2026
FEAC 0.02% 2,085 $ 4,566.15 Jun 30, 2026
RESM 0.01% 149 $ 326.31 Jun 30, 2026
FSEV 0.01% 172 $ 376.68 Jun 30, 2026
DFSU 0.00% 19,333 $ 15.853K Nov 12, 2026
DXUV 0.00% 43,269 $ 35.481K Nov 12, 2026
DFAC 0.00% 166,283 $ 136.352K Nov 12, 2026